A Study to Evaluate ALN-2232 in Participants With Obesity
Key facts
- Where
- Mount Royal, CanadaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07463846, who can take part
Where in Canada
- Mount RoyalMount Royal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alnylam Pharmaceuticals
- Trial code
- NCT07463846
- Record updated
- 13 October 2026
- Original description
The purpose of this study is to:Read full original descriptionShow less
A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-2232 as Monotherapy and Co-initiated With Tirzepatide in Adult Participants With Obesity
The purpose of this study is to:
* evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
Inclusion: All Parts:; Has a body mass index (BMI) of ≥30 kg/m\^2 and <40 kg/m\^2; Has a hemoglobin A1c (HbA1c) <6.5%.
Exclusion: Receiving therapies for chronic weight management or antidiabetic medications; Note: other protocol defined inclusion/exclusion criteria apply; Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results; All Parts:.